Your Source for BioScience Venture Capital Data
  • OnBioVC NEWS:

    - OnBioVC Announces Beta Launch of Service
    - OnBioVC INDEX(TM) Updated thru JUN 2010
    - OnBioVC 2Q10 Trend Analysis, now available
    - OnBioVC 3Q10 Trend Analysis, coming soon
  • SEARCH THE OnBioVC DATABASE:

  • investment bank middle market venture capital

Trevena (Berwyn, PA) a clinical-stage small molecule company focused on G-protein coupled receptor targeting for heart failure and pain, closed a $35M Series B funding from existing investors. Participants include Polaris Venture Partners, New Enterprise Associates, Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company.

Incline Therapeutics (Redwood City, WA) a clinical-stage drug:device combo company focused on pain, closed a $43M Series A financing. Participants include Frazier Healthcare Ventures, 5AM Ventures, Technology Partners, Adams Street Partners, Saints Capital Partners and Emergent Medical Partners.

NeuroTherapeutics Pharma (Chicago, IL) a clinical-stage biopharmaceutical company focused on the CNS disorders of epilepsy, acute and neuropathic pain, closed a $43M Series B financing. Participants include Fidelity Biosciences, MPM Capital, S.R. One, Pfizer, Novo Ventures and Thomas McNerney & Partners.

Astute Medical (San Diego, CA) a development-stage diagnostic company focused on the identification and validation of protein biomarkers that can test for hospital acquired acute conditions like sepsis, kidney injury and abdominal pain, closed a $26.5M Series B financing. Participants include Domain Associates, Delphi Ventures, Johnson & Johnson Development Corp. and De Novo Ventures.

Tragara Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on selective biomarker for oncology, pain and inflammation therapeutics, closed a $5M Series B financing. Participants include Domain Associates, Mitsubishi Corp., Morgethaler Ventures, Oxford Bioscience Partners and ProQuest Investments.

Archimedes Pharma (United Kingdom) a commercial-stage specialty oncology company focused on pain and critical care, closed a $99M Series C financing. Participants include Novo Growth Equity and Warburg Pincus.

Nautilus Neurosciences (Bridgewater, NJ) near commercial-stage specialty neurology pharma focused on migraine and acute pain, closed a $14.5M Series A financing. Participants include Tailwind Capital.
_________________________________________________________________________
NOTE: New OnBioVC Friday feature coming, well…this Friday!

Afferent Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on pain associated with conditions such as osteoarthritis, back pain, visceral pain and neuropathy, closed a $23M Series A financing. Participants include Third Rock Ventures, Pappas Ventures, Domain Associates and New Leaf Venture Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

SantoSolve (Norway) a clinical-stage biopharmaceutical company focused on topical analgesic products based on non-radioactive strontium for various pain conditions, closed a $5.5M Series C financing. Participants include Teknoinvest, InnovationsKapital and Investinor.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Zogenix (San Diego, CA) a clinical-stage drug:device company focused on a needle-free delivery system of chronic pain therapeutic, closed a $51M Series B financing. Participants include Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, Oxford Finance and Abingworth Management.

« Previous Entries  

to top of page...